NVAX Q2 2019 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-68.8% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$37M-1092.2% margin

Net Income

-$40M-1179.7% margin

EPS (Diluted)

$-1.69

QoQ Revenue Growth

-15.7%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$189M

Total Liabilities

$375M

Stockholders' Equity

-$185M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$11M	-68.8%
Gross Profit	$3M	$11M	-68.8%
Operating Income	-$37M	-$42M	+12.7%
Net Income	-$40M	-$44M	+11.0%

Revenue Segments

Grant

$3M100%